Additional Details
-
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
GSK Investigational SiteDurham NC. 27710 -
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
GSK Investigational SiteLos Angeles CA. 90033 -
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
GSK Investigational SiteLos Angeles CA. 90095 -
Telehealth and Onsite Maintenance Exercise in Chronic Lung Disease
MGH Institute of Health ProfessionsCharlestown MA. 02129 -
Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients
UCLA Health Westwood Medical PlazaWestwood CA. 90095 -
Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients
Washington University (Site #: 71191)Saint Louis MO. 63130 -
Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients
NYU Langone Health (Site #: 71177)New York NY. 10016 -
Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients
University of Pennsylvania (Site #: 71111)Philadelphia PA. 19104 -
Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients
Cincinnati Children's Hospital Medical Center (Site #: 71017)Cincinnati OH. 45229 -
Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients
University of California, Los Angeles (Site #: 71123)Los Angeles CA. 90095 -
Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients
Cleveland Clinic (Site #: 71101)Cleveland OH. 44195 -
Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients
Johns Hopkins (Site #: 71119)Baltimore MD. 21287 -
Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients
Duke University (Site #: 71139)Durham NC. 27710 -
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
MD Anderson Cancer CenterHouston TX. 77030 -
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
Research SiteTrois-Rivières QC. G8T 7A1 -
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
Research SiteAjax ON. L1S 2J5 -
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
Research SiteMontréal QC. H2X 0A9 -
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
Research SiteEdmonton AB. T6G 2C8 -
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
Research SiteSherbrooke QC. J1H 5N4